DPTIP-prodrug18 is an orally bioavailable, blood-brain barrier-permeable prodrug of DPTIP (HY-131002) and a potent inhibitor of neutral sphingomyelinase 2 (nSMase2). It significantly suppresses IL-1β-induced extracellular vesicle (EV) release by inhibiting nSMase2 activity. DPTIP-prodrug18 can be used in the study of brain injury.